**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 62585

**Manuscript Type:** MINIREVIEWS

**Obesity, metabolic health and omics: Current status and future directions**

Paczkowska-Abdulsalam M *et al*. Metabolically healthy obesity and omics

Magdalena Paczkowska-Abdulsalam, Adam Kretowski

**Magdalena Paczkowska-Abdulsalam, Adam Kretowski,** Clinical Research Centre, Medical University of Bialystok, Bialystok 15-276, Poland

**Adam Kretowski,** Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok 15-276, Poland

**Author contributions:** Paczkowska-Abdulsalam M performed the literature review and wrote the manuscript which was critically revised for important intellectual content by Kretowski A; both authors approved the final version of the article.

**Corresponding author: Magdalena Paczkowska-Abdulsalam, PhD, Research Fellow,** Clinical Research Centre, Medical University of Bialystok, Sklodowskiej-Curie 24A, Bialystok 15-276, Poland. magdalena.paczkowska@umb.edu.pl

**Received:** January 12, 2021

**Revised:** February 22, 2021

**Accepted:** March 29, 2021

**Published online:**

**Abstract**

The growing obesity epidemic is becoming a major public health concern, and the associated costs represent a considerable burden on societies. Among the most common complications of severe obesity are the development of hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, and various types of cancer. Interestingly, some obese individuals have a favorable metabolic profile and appear to be somehow protected from the detrimental effects of excessive adipose tissue accumulation. These individuals remain normoglycemic, insulin sensitive, and hypotensive with proper blood lipid levels, despite their high body mass index and/or waist circumference. Multiple independent observations have led to the concept of the metabolically healthy obese (MHO) phenotype, yet no consensus has been reached to date regarding a universal definition or the main mechanism behind this phenomenon. Recent technological advances and the use of high-throughput analysis techniques have revolutionized different areas of biomedical research. A multi-omics approach, which is used to investigate changes at different molecular levels in an organism or tissue, may provide valuable insights into the interplay between the molecules or pathways and the roles of different factors involved in the mechanisms underlying metabolic health deterioration. The aim of this review is to present the current status regarding the use of omics technologies to investigate the MHO phenotype, as well as the results of targeted analyses conducted in MHO individuals.

**Key Words:** Metabolically healthy obesity; Cardiovascular diseases; Genomics; Transcriptome profiling; Proteomics; Metabolomics

Paczkowska-Abdulsalam M, Kretowski A. Obesity, metabolic health and omics: Current status and future directions. *World J Diabetes* 2021; In press

**Core Tip:** Multiple independent observations have led to the concept of the metabolically healthy obese (MHO) phenotype, in which individuals, despite a high body mass index, remain normoglycemic, insulin sensitive, and hypotensive with proper blood lipid levels. Even though this issue is of great interest to the scientific community, no consensus has been reached to date regarding the main mechanism behind this phenomenon. The aim of this review is to present the current status regarding the use of omics technologies to investigate the MHO phenotype at different molecular levels, as well as the results of targeted analyses conducted in MHO individuals.

**INTRODUCTION**

Over the past several decades, the incidence of obesity has tripled worldwide[1]. The high amounts of excess or abnormal adipose tissue, together with all the related comorbidities, are imposing a considerable burden on societies, and obesity has become a major public health concern. Among the most common complications of severe obesity are the development of hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease (CVD), and various types of cancer[2]. There are, however, some obese individuals who exhibit a favorable metabolic profile. These individuals remain normoglycemic, insulin sensitive (IS), and hypotensive with proper blood lipid levels, despite their high body mass index (BMI) and/or waist circumference (WC). Based on multiple independent observations, the concept of the metabolically healthy obese (MHO) phenotype[3,4] has been proposed, yet no consensus has been reached to date regarding a uniform definition or the main mechanism behind this phenomenon.

***Definition and prevalence***

More than 30 sets of criteria for the MHO phenotype have been used in different clinical studies over the years, and most have included parameters such as BMI, blood pressure, fasting plasma glucose, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), WC, and homeostasis model assessment of insulin resistance[5]. The inconsistencies between studies are mostly related to different cutoff values for the parameters or the number of criteria that have to be met to define the MHO phenotype[6,7]. Furthermore, some researchers have applied metabolic syndrome (MetS) definitions, while others have defined metabolic health based on insulin sensitivity[8] or liver fat[9]. The variabilities in the criteria used in studies represent a significant limitation, complicating the interpretation and comparison of research results. This issue may also, in part, explain the discrepancies in the reported prevalence of the MHO phenotype, which has differed between studies depending on the type of population studied and definition used. For example, Liu *et al*[10] reported a prevalence that ranged from 4.2% to 13.6%, whereas that reported by Rey-López *et al*[11] ranged from 6% to 75%. A recent meta-analysis of data from 12 cohort and 7 intervention studies found that almost one-third of obese individuals were metabolically healthy[12]. In general, the prevalence of the MHO phenotype has been found to be higher in women and younger study participants[11,13]. Metabolically healthy individuals have also been observed to be less sedentary and more physically active than their unhealthy counterparts[14].

***MHO phenotype and associated risks***

The lack of clearly defined diagnosis criteria for the MHO phenotype has also led to inconsistent results among studies evaluating the association between the metabolic health status and the risk of CVD, type 2 diabetes development, and mortality. Some epidemiological studies with short-term follow-ups have reported that MHO individuals have a similar risk of incident CVD as metabolically healthy normal weight (MHNW) individuals. On the other hand, more recent studies with long follow-ups have found that MHO individuals have a higher risk of CVD and cardiovascular mortality than healthy non-obese subjects[15]. A meta-analysis by Eckel *et al*[16] revealed that study participants with the MHO phenotype had a higher risk of developing CVD than MHNW individuals and a lower risk than metabolically unhealthy normal weight subjects, regardless of the MHO definition. Similar results were obtained by Bell *et al*[17], who investigated the incidence of type 2 diabetes among MHO individuals and found that their risk of developing diabetes mellitus was approximately half that of metabolically unhealthy obese (MUO) subjects; however, the risk was significantly higher in MHO individuals than in MHNW individuals. The most recent meta-analysis, which included 23 studies, found an increased risk of CVD in the MHO group compared with healthy lean subjects[18]. Interestingly, in this meta-analysis, the risk of CVD in MHO individuals was similar even when different numbers of risk factors were used to define good metabolic health and remained high even when none of the metabolic abnormalities were present. The MHO group was found to have a significantly increased risk of all-cause mortality, but not cardiovascular mortality, when compared to the MHNW group[18].

***Mechanisms underlying the MHO phenotype***

Although MHO individuals have a favorable metabolic profile, it remains unclear whether this protection from the detrimental consequences of obesity is permanent or temporary. A recent meta-analysis including 5914 MHO individuals revealed that half of them experienced a deterioration of their metabolic health over time[12]. The Multi-Ethnic Study of Atherosclerosis, which was based on data from 6809 individuals, found that the MHO phenotype was not significantly associated with the incidence of CVD; however, half of the population in the study developed MetS during the follow-up period. The conversion from the MHO to MUO phenotype was found to result in a substantially increased CVD risk. Interestingly, study participants with a stable MHO phenotype were found to have a comparable risk as MHNW subjects[19]. Therefore, maintaining a healthy metabolic status appears to be a valid approach for preventing cardiometabolic diseases.

Despite the great interest of the research community, little is known about the exact mechanism responsible for a favorable metabolic profile in the presence of obesity. Several factors and phenotypic traits have been described, including normal adipose tissue function, low liver fat content, low visceral and ectopic fat volume, preserved insulin sensitivity, and low levels of inflammation[20]. Several studies have also suggested that genetic predisposition[21], circulating micro-RNAs (miRNAs)[22], or gut microbiota[23] may play a role (Figure 1).

***Aim of the review***

Given all these discrepancies and the rather unclear understanding of the underlying mechanisms, this review article aims to provide an overview of the current state of knowledge regarding the results of different omics studies that have investigated the MHO phenotype. In some cases, because of the lack of genome-wide analyses, the results of targeted studies are presented. We believe that this multi-level approach will help to better understand the mechanisms behind healthy obesity. With the recent progress in technology, it is now possible to study processes on different molecular levels in detail and on a wide scale (Figure 2). Therefore, we performed extensive searches in the PubMed database for articles that were published between 2010 and 2020. The following search terms in a variety of combinations were used: ‘healthy obesity’, ‘MHO’, ‘metabolically healthy obese’, ‘genomics’, ‘transcriptomics’, ‘gene expression’, ‘proteomics’, ‘metabolomics’, ‘gut microbiota’, ‘epigenomics’, and ‘miRNA’.

**GENOMICS**

It is well established that genetic factors contribute to the development of obesity[24]; however, their role in metabolic health deterioration in obese individuals is still being clarified[21]. Even though genetic predisposition cannot be changed, being aware of the presence of certain variants allows the modification of environmental factors, which can delay or prevent the development of a disease or condition. Genome-wide association studies help to identify the link between a single nucleotide polymorphism (SNP) and a particular disorder[25].

In a study by Schlauch *et al*[26], 89 out of 905027 investigated SNPs showed an association with the MHO phenotype, which was defined by following characteristics: BMI ≥ 35 kg/m2, normal blood pressure, normal fasting plasma glucose (less than 100 mg/dL), and a desirable fasting lipid panel based on the National Cholesterol Education Panel Adult Treatment Panel III (NCEP ATP III) recommendations. Interestingly, all 89 SNPs identified in this study were located within intergenic regions, or non-coding regions, of their respective genes. Further analysis revealed that 12 genes associated with significant SNPs had been previously linked to obesity or cardiometabolic disease: *DPYD* to syndromic obesity, *KLHL6* to acute insulin response to glucose, *RTP4* to future incidence of hypertension, *PCDH7* to WHR, *FSTL4* to increased risk of stroke, *CSMD1* to MetS, *ITIH5* to BMI, *KCNQ1* to type 2 diabetes, *NBEA* to increased diastolic BP, *BBX* to type 1 diabetes, and *NTRK2* to obesity and depression. Furthermore, 31 polymorphisms were observed to be located close to at least one other SNP within the same gene or intergenic region, suggesting their special relevance according to the authors. A different study reported a significant association of *FTO* (rs1121980) and *TCF7L2* (rs7903146) genetic variants with maintaining metabolic health in obese women, who did not develop MetS according to joint interim statement criteria[27]. In addition, a genetic variant of *SLC39A8* (rs13107325) was found to have a statistically significant association with metabolic health status in a subgroup of postmenopausal women. The *TCF7L2* and *SLC39A8* genetic markers were shown to have a protective effect and help preserve metabolic health status, while the other marker was found to increase the risk of transitioning from the MHO to MUO phenotype. The same *FTO* genetic marker (rs1121980) was demonstrated to have a significant association with the MUO but not MHO phenotype in a previous genotyping study, which also applied joint interim statement MetS definition[28].

Gao *et al*[29] investigated the association of SNPs of the *MC4R* gene with the MHO and MUO phenotypes in a Chinese population and found that rs2331841 increased the genetic risk of the MUO phenotype. Metabolically healthy subjects were defined as having less than two of the metabolic abnormalities in the NCEP ATP III criteria, while metabolically abnormal patients had at least two abnormalities. Based on the results of their study, the authors suggested that the rs2331841 SNP was associated with not only obesity but also metabolic abnormalities in obese subjects. Another group of researchers focused on the lactoferrin (*LTF*) gene-related polymorphisms and observed significant differences in the genotype frequencies of *LTF* rs2239692 between MHO and MUO individuals[30]. The CT variant of *LTF* rs2239692 was found to significantly decrease the risk of MetS development in obese individuals. Two other studies have reported an association of the adiponectin rs2241766 genetic variant with metabolic health phenotypes[31,32]. One reported more than a two-fold increase in the risk of developing metabolic abnormalities in the presence of the T45T genotype, while the second one found that the adiponectin T45G polymorphism was associated with the progression from the MHO to MUO phenotype. Both studies used International Diabetes Federation (IDF) MetS criteria to identify metabolically healthy individuals. The genetic variants associated with the MHO phenotype are presented in Table 1.

**TRANSCRIPTOMICS**

***Gene expression***

In recent years, transcriptome profiling has become one of the most common approaches for investigating diseases on a molecular level[33]. Gene expression profiling provides valuable information about any alterations in biological processes, and this information is crucial for not only understanding the underlying mechanisms but also making a molecular diagnosis and selecting a clinical therapy for the condition under study. The methods most widely used in gene expression studies are real-time reverse transcription polymerase chain reaction (RT-PCR), microarrays, and next-generation sequencing. Only a few research groups have applied a genome-wide approach to identify gene expression alterations in the MHO phenotype (Table 2). Gaye *et al*[34] performed whole blood transcriptome sequencing on samples from 8 MHO and 21 MUO individuals. The top 10 of the 149 enriched GO terms were related to mRNA translation processes. The canonical pathway analysis conducted in QIAGEN’s Ingenuity Pathway Analysis (IPA) revealed significant enrichment in EIF2 signaling, regulation of eIF4 and p70S6K signaling, and mTOR signaling pathways. Of note, the top differentially expressed genes were ribosomal protein genes. The authors stated that the MUO subjects exhibited higher levels of ribosomal and endoplasmic reticulum (ER) stress and inflammation than the MHO individuals. They also noted that the TG/HDL-C ratio was possibly the major driver of the altered expression of ribosomal protein genes in these two groups. The authors proposed controlling ER and ribosomal stress and keeping the TG/HDL-C ratio in the proper range as potential strategies to prevent the development of an unfavorable metabolic profile in obese individuals.

We found that similar pathways were enriched in our recent transcriptomic study of different metabolic health phenotypes[35]. The IPA core analysis of differentially expressed genes between MHO and MHNW subjects revealed significant enrichment in EIF2 signaling, regulation of eIF4 and p70S6K signaling, oxidative phosphorylation, mitochondrial dysfunction, and mTOR signaling canonical pathways. Moreover, a vast majority of the genes within each of the identified pathways were upregulated. We also compared gene expression patterns between MUO and MHO individuals and found enrichment in canonical pathways associated with processes of inflammation, coagulation and thrombosis, hepatic fibrosis, and atherosclerosis signaling. Another study used whole genome microarrays to evaluate gene expression in the peripheral blood of obese individuals with and without metabolic disturbances[36]. The data analysis revealed enrichment in genes involved in lipid metabolism, carbohydrate metabolism, protein synthesis, and the activation, signaling, and function of cells. Another microarray study analyzed gene expression in abdominal subcutaneous adipose tissue samples from MHO and MUO subjects[37]. The authors performed unsupervised hierarchical clustering of 1595 obesity-associated transcripts and identified two obesity subtypes among the study participants. Differentially expressed genes between the two groups were mainly enriched in CVD pathways (occlusion of artery, vascular disease, peripheral arterial occlusive disease) and immune and inflammatory response pathways (complement system, TREM1 signaling, interleukin-8 signaling).

Targeted gene expression analyses of the MHO phenotype have been much more common. In one study, five out of six investigated mitophagy genes showed no significant differences in expression between MHO and metabolically healthy non-obese subjects[38]. The authors concluded that unaltered mitophagy allowed the control of oxidative stress and inflammation, leading to improved mitochondrial function and preserved insulin sensitivity in MHO subjects. An earlier study reported lower levels of oxidative and ER stress in MHO individuals based on the results of a gene expression experiment focusing on genes involved in the regulation of the unfolded protein response[39]. Another research group investigated a set of proinflammatory genes and found no significant differences between abdominally obese MHO and MUO subjects[40,41]. The two groups were matched for abdominal fat, and because of this matching, the authors suggested that the expression levels of Toll-like-receptor (TLR) 2, TLR4, TRIF, MyD88, and nuclear factor-κappa beta (NF-𝜅B) were related more to abdominal obesity than to metabolic health status. Telle-Hansen *et al*[42] analyzed the expression of selected genes involved in lipid uptake, transport, lipolysis, lipogenesis, and fatty acid oxidation and found reduced gene expression of *UCP2*, *LIPE*, and *PPARG* in the MUO group compared to that in the MHO group, while no differences were observed between MHO and MHNW individuals. A different research group analyzed the expression of inflammatory and matrix remodeling genes in visceral adipose tissue (VAT) and liver tissue samples from MHO and MUO subjects and found similar gene expression profiles between the groups in both tissues[43].

***miRNAs***

miRNAs are short non-coding RNA molecules consisting of around 22 nucleotides[44]. They have been proven to be important gene expression regulators, and most human protein-coding genes are regulated by at least one miRNA[45]. They exert their function through binding to target mRNAs, which results in mRNA translational repression or transcript degradation, depending on the degree of base-pairing complementarity[46]. Specific miRNA signatures have been described in many diseases, including obesity, type 2 diabetes, and CVD[22]. To date, however, only a few studies have investigated miRNAs in the MHO phenotype. The molecules that have been identified in MHO subjects by different research groups are presented in Table 3.

In a recent study, Yang *et al*[47] used microarrays to analyze miRNA levels in plasma samples from six young MHO individuals and six healthy controls. Individuals with diabetes mellitus, hypertension, hyperlipidemia, coronary artery disease, valvular or congenital heart disease, cardiomyopathy, atrial fibrillation, and heart failure were excluded from the study. A distinct miRNA profile was identified for the MHO phenotype. Gene ontology analysis revealed the highest enrichment in the following terms: cell-cell adhesion, translational initiation, and apoptotic process among biological processes; nucleoplasm and nucleus among cellular components; and protein binding, DNA binding, and protein serine/threonine kinase activity among molecular functions. The expression levels of six of the top ten up- or downregulated miRNAs were further confirmed in a group of 600 MHO subjects in a RT-PCR experiment. MiRNA-500, miRNA-454, and miRNA-320a were found to be downregulated in MHO individuals, while miRNA-21, miRNA-148a, and miRNA126 were found to be upregulated. The authors reported that high circulating miRNA-21 Levels were associated with impaired diastolic function as well as increased cardiac fibrosis markers *via* the TGF-β1/Smad signaling pathway. A different set of miRNAs was identified in another study, which screened 179 serum miRNAs in a group of MHO and MUO individuals[48]. The authors applied a stringent inclusion criteria of three distinct definitions of MHO: the basic definition; the modified Wildman definition; and the most stringent definition which adds an inflammation marker to all parameters included in the modified Wildman definition. One of the eight differentially expressed miRNAs, identified in this study, remained significant after validation in an independent sample of 98 obese subjects with/without metabolic abnormalities. According to the authors, the differences in miRNA-374-5p expression between the MHO and MUO phenotypes were related to the TG/HDL-C ratio. Based on an analysis in an independent cohort, they also stated that miRNA-374-5p may modulate CCL2 expression, which is a pro-inflammatory marker, upstream of the pathway leading to dyslipidemia in obesity.

A more recent study applied a targeted RT-PCR approach and found significantly higher serum miRNA-503 Levels in MHO and MHNW subjects than in MUO individuals[49]. It was found that miRNA-503 negatively correlated with metabolic abnormalities in obese subjects, and the authors concluded that miRNA-503 can serve as a biomarker to distinguish between the MHO and MUO phenotypes, which were defined according to the 2007 Joint Committee for Developing Chinese Guidelines. Another study defined good metabolic health as being IS despite concurrent obesity[50]. Fifteen miRNAs were observed to be differentially expressed in subcutaneous white adipose tissue between IS and insulin resistant (IR) obese women. In further functional *in vitro* studies, the authors concluded that miRNA-143-3p and miRNA-652-3p might enhance insulin-stimulated glucose incorporation into lipids in human fat cells. Jones *et al*[51] analyzed 175 miRNAs in the plasma of IS and IR obese women and healthy controls. MiRNA-335 and miRNA-423-5p were found to be differentially expressed between the IR and IS groups. The authors also compared the miRNA profiles of the IS obese and healthy control groups and reported the top ten up- and downregulated molecules with different expression levels in each of the groups.

**DNA METHYLATION**

DNA methylation is an epigenetic mechanism involving the covalent addition of methyl groups to nucleotide bases, usually cytosines in CpG dinucleotide sequences. It affects gene expression levels by regulating interactions with transcriptional activators and repressors, as well as chromatin remodeling enzymes[52]. This heritable genetic marker is considered to play a major role in the epigenetic suppression of the transcription process. Differentially methylated regions have been described in a variety of conditions, including type 2 diabetes, cancers, and autoimmune and neurological disorders[53]. Only a few studies, however, have investigated this type of DNA modification and its association with the MHO phenotype.

A group led by Turcot analyzed the methylation levels of long interspersed nuclear element 1 (*LINE-1*) repetitive elements in VAT samples from obese individuals with and without MetS[54]. As *LINE-1* is considered to be a marker of genome-wide methylation, the authors concluded that lower global DNA methylation levels were associated with a greater risk of MetS in the presence of obesity. A year later, the same group reported that they found no association between dipeptidyl peptidase-4 (*DPP4*) methylation levels and metabolic health status[55]. In their study, Guénard *et al*[56] applied a genome-wide approach to analyze altered biological pathways in VAT samples from obese men with and without metabolic abnormalities, which were defined by NCEP ATP III MetS definition. Using differential methylation analysis, they identified 8578 CpG sites with significant differences between the groups. Some of them were located within genes previously described as being related to processes of cellular growth and proliferation (*PRKCA, PPP2R2B*), lipid metabolism (*FASN, LRP1B, PLA1A*), or inflammation (*IL17RA*). Of note, the *RPTOR* gene, which regulates cell growth in response to nutrient and insulin levels, was found to contain 28 differentially methylated sites[56]. The subsequent enrichment analysis revealed pathways related to hepatic cholestasis, renin-angiotensin signaling, cell cycle regulation (cdc42 signaling, inositol phosphate metabolism), inflammation and immunity (antigen presentation pathway, autoimmune diseases signaling), and structural components of the cell membrane (glycerophospholipid/phospholipid metabolism).

**PROTEOMICS**

Proteomics enables the genome-wide identification and quantification of all proteins present at a certain moment in a cell or tissue of interest. It can provide valuable insight into the molecular basis of a studied condition, disease, or phenotype at the protein level. Proteomics-based approaches are widely applied in different research areas, and they often lead to the discovery of novel biomarkers or drug targets[57]. The proteome of the MHO phenotype has also been studied by a few research groups (Table 4). In one study, a serum analysis of 20 African-American women was performed, and 20 differentially expressed proteins were identified between the MHO and MUO groups[58]. Metabolically healthy subjects fulfilled criteria of all three distinct definitions of the MHO phenotype: the basic definition; the modified Wildman definition; and the most stringent definition which adds an inflammation marker to all parameters included in the modified Wildman definition. Pathway analysis revealed enrichment in inflammatory and lipid pathways, including LXR/RXR (liver X receptor/ retinoid X receptor) and FXR/RXR (farnesoid X receptor/retinoid X receptor) activation, atherosclerosis signaling, acute phase response signaling, and the complement system. Overall, lower levels of pro-inflammatory and higher levels of anti-inflammatory markers were observed in the MHO status than in the MUO status. A more recent study investigated changes in the urinary proteome of 18 obese individuals with different metabolic statuses defined by the IDF MetS criteria[59]. The authors detected 54 proteins with altered expression, and most were related to the NF-𝜅B and p38 mitogen-activated protein (MAP) kinase pathways. The MUO study participants were found to have a higher abundance of proteins involved in inflammation (FIBA, TRFE, KNG1) and insulin resistance (ARL15, RET4) than the MHO individuals. In another study, 28 differentially expressed proteins were identified in VAT samples obtained from 18 patients undergoing bariatric surgery who had previously been divided into MHO and MUO groups according to the IDF MetS definition[60]. The differentially expressed proteins belonged to three functional categories: protein and lipid metabolism, cytoskeleton, and regulation of other metabolic processes. The top overrepresented IPA canonical pathways included death receptor signaling, coagulation system, acute phase response signaling, Rho GDI signaling, and NRF2 (nuclear factor erythroid 2-related factor 2)-mediated oxidative stress response. The proteins that were found to be upregulated in MHO individuals were mainly cytoskeletal and antioxidant proteins, as well as proteins involved in mitochondrial import and transcriptional activity. The MUO individuals, on the other hand, were found to exhibit the upregulation of proteins that increase metabolic dysfunction in the ECM, mitochondria, and lipid droplets. The authors noted that the differentially expressed proteins were involved in complex pathways linked to insulin dysregulation. Doulamis *et al*[61] used a targeted proteomic approach to measure 30 potential biomarkers in serum and VAT samples from 28 obese patients undergoing bariatric surgery. The metabolic health status was defined as the presence (MUO) or absence (MHO) of comorbidities such as hypertension, dyslipidemia and diabetes mellitus. Compared to the levels in MUO individuals, six downregulated proteins in VAT (TWEAK, TRAIL, GDF-15, RETN, MMP-9, ICTP) and four downregulated proteins in serum (interleukin-20, PROK-1, TWEAK, CCL-3) were identified in MHO individuals. Those with the MUO phenotype were found to exhibit increased inflammation and higher levels of pro-inflammatory markers not only locally in adipose tissue but also systemically in the peripheral blood.

**METABOLOMICS**

Metabolomics is an emerging technology used to analyze all small molecule compounds that are products or substrates of chemical reactions within a biological system (cell, tissue, or organism)[62]. It provides comprehensive information on the activity and status of cellular and organismal metabolism and is therefore widely applied in different settings to identify metabolic disturbances underlying a disease, novel biomarkers, or new therapeutic targets[63]. The analysis of the molecular composition of a sample is carried out through the use of nuclear magnetic resonance (NMR) or mass spectrometry (MS). Both liquid and gas chromatography are applied to separate metabolites[62].

Several research groups that have investigated the MHO phenotype have performed metabolomic profiling experiments using NMR technology. A study on overweight and obese women with and without MetS in Finland found significant differences in branched-chain amino acids (BCAAs), aromatic amino acids (AAAs), orosomucoid, several species of fatty acids, and phospholipids between metabolically healthy and MetS study participants[64]. Of note, orosomucoid, BCAAs, and AAAs were associated with all MetS risk factors. A more recent study identified higher levels of alanine, glutamine, proline, asparagine, L-glutathione reduced, betaine, taurine, choline, 2-aminobutyrate, tagatose, and 2-oxoglutarate in MHO individuals than in MUO individuals[65]. Additionally, lower levels of L-alpha-phosphatidylinositol and D-sphingosine were observed in MHO subjects. A pathway enrichment analysis that compared MUO and MHO subjects revealed alterations in the urea cycle, ammonia recycling, aspartate metabolism, and glycine and serine metabolism, among other pathways (Table 5).

A research group led by Telle-Hansen *et al*[42] reported that the concentrations of very low-density lipoprotein, intermediate-density lipoprotein, and low-density lipoprotein subclasses were, overall, significantly higher in MUO individuals than in MHO individuals, with the MHNW group having the lowest values. In addition, the levels of HDL subclasses were lower in MUO and higher in MHNW individuals than in the MHO group; together, these results indicate that MHO subjects have an intermediate CVD risk profile compared to those of MUO and MHNW individuals. Similarly, an earlier study that used gas chromatography-MS analysis reported that the MHO group had an intermediate serum amino acid profile compared to those of MHNW and MUO subjects[66]. Even though most individual amino acids did not differ significantly between the MHO and MUO groups, several of them, including glycine, reflected the intermediate cardiometabolic profile of the MHO phenotype. Overall, the results suggested improved insulin sensitivity in the MHO group compared to that in the MUO group, as well as differences between the two groups in the availability of metabolites that enter the TCA cycle. Hydroxyproline concentration together with the ratios of other amino acids were proposed as biomarkers for distinguishing between the MHO and MUO phenotypes.

In their study, Chen *et al*[67] identified a group of serum metabolites, including L-kynurenine, glycerophosphocholine, glycerol 1-phosphate, glycolic acid, tagatose, methyl palmitate, and uric acid, that differed significantly between the MHO and MUO groups. In addition, they found that several metabolic pathways, such as fatty acid biosynthesis, phenylalanine metabolism, propanoate metabolism, and valine, leucine, and isoleucine degradation, were altered between the two phenotypes. The authors reported an association of liver and mitochondria functions with metabolic disturbances in obese subjects. Another metabolomics study reported that the plasma metabolic profiles of MetS obese individuals correlated with the fulfillment of a number of criteria used to diagnose MetS[68]. Fifteen metabolites, including nucleosides, amino acids and derivatives, amino sugars, purine derivatives, and polyols, that could differentiate between metabolically healthy and unhealthy individuals were identified. These metabolites with altered concentrations belonged to numerous physiologically significant pathways, such as purine metabolism; valine, leucine, and isoleucine degradation; aminoacyl-tRNA biosynthesis; and tryptophan metabolism. A case control study that included over 100 MHO individuals reported that BCAAs, glutamic acid, tyrosine, and a specific pattern of lysophosphatidylcholines were associated with both the MHO and MUO phenotypes[69]. Interestingly, when the MUO and MHO phenotypes were directly compared, no significant differences in metabolites were found. Another study highlighted the importance of body fat distribution and performed a metabolomic analysis of serum samples from metabolically healthy peripherally obese and metabolically unhealthy centrally obese individuals[70]. The authors found that significantly higher levels of BCAAs (leucine, isoleucine, valine), propionylcarnitine (C3 acylcarnitine), and alpha-aminoadipic acid could distinguish metabolically unhealthy central obesity from metabolically healthy peripheral obesity.

To better understand the role of visceral fat in the development of metabolic abnormalities, Candi *et al*[71] analyzed the metabolomic profiles of VAT samples from MHO and MUO subjects. They found that the state of pathological obesity was associated with the increased metabolism of γ-glutamyl amino acids, which are involved in glutathione metabolism and the response to oxidative stress, and plasmalogens, which contribute to insulin resistance and hypertension[72].

**MICROBIOME**

Increasing evidence suggests that the human gut microbiota has a significant impact on maintaining immune and metabolic homeostasis and protecting against pathogens[73]. Changes in the composition of intestinal bacteria have been reported in a variety of disorders, including neurological, cardiovascular, and respiratory illnesses[74]. The most popular method for studying the human endogenous microbial community is 16S rRNA sequencing, which can effectively distinguish between different taxa[75]. To date, only a few research groups have investigated the association between gut microbiota and the MHO phenotype. Kim *et al*[76] profiled fecal microbiota from over 700 overweight and obese Korean individuals who had no metabolic abnormality (metabolically healthy) or had at least one metabolic abnormality (metabolically unhealthy). To define metabolic abnormalities the NCEP ATP III criteria were used. Genera such as *Oscillospira* and *Clostridium* were found to be significantly more abundant in metabolically healthy individuals, and the results were similar for the family Coriobacteriaceae within *Actinobacteria* and the family Leuconostocaceae within Firmicutes. On the other hand, metabolically unhealthy individuals were found to have an increased abundance of Fusobacteria. Interestingly, no differences in the Firmicutes/Bacteroidetes ratio between the two groups were observed. Of note, the microbial profile of metabolically healthy overweight/obese subjects was closer to that of lean individuals than to that of metabolically unhealthy overweight/obese individuals. A study on obese Mexican women with and without MetS reported that three genera and families were significantly enriched in the obese without MetS group: *Roseburia*, *Succinivibrio*, and S24-7 (all were three-fold more abundant than in the MetS obese and control groups)[77]. Another study, in which the NCEP ATP III MetS definition was applied to define the metabolic status of older Irish individuals, reported no differences in the diversity, richness, or taxonomy between the MHO and MUO groups[78]. A different approach was applied by Kashtanova *et al*[79], who analyzed the association of the gut microbiota composition with individual cardiovascular risk factors. An increase in the abundance of certain genera was observed depending on the type of metabolic abnormality: *Blautia* in cases of impaired carbohydrate metabolism and *Prevotella* in individuals with elevated BP and obesity. The abundance of *Serratia* increased together with a number of cardiovascular risk factors, whereas an inverse relationship was observed between the abundance of *Oscillospira* and abdominal obesity.

**CONCLUSION**

As evidenced by the findings discussed in this review, over the past several years, enormous progress has been made regarding the molecular characterization of different metabolic health phenotypes. The studies conducted to date are a source of valuable information on the protective mechanisms underlying the MHO phenotype or the mechanisms responsible for metabolic health deterioration and the transition from the MHO to MUO phenotype. Genomic studies have identified genetic variants that are related to increased adiposity with a favorable metabolic profile. Many of the identified loci are located near genes previously reported to be involved in insulin signaling, insulin resistance, fat distribution, and adipogenesis. The results of transcriptomic analyses suggest that mitochondrial dysfunction, ER and oxidative stress, pathological changes in the liver, and activated atherosclerotic processes contribute to the development of metabolic abnormalities. Moreover, miRNA profiling studies have identified several molecules that are characteristic of the MHO phenotype, some of which are involved in processes such as cell-cell adhesion, translational initiation, and the apoptotic process. Epigenomic analyses have revealed differences in the methylation of sites within genes involved in lipid metabolism, inflammation, and cellular growth. Similar pathways have been found to be altered within the proteomes of different metabolic health phenotypes. Metabolomics has been used to confirm the important role of liver and mitochondria functions in metabolic disturbances, while significant differences in the gut microbiota composition have been found between MHO and MUO individuals.

Nevertheless, multiple issues still need to be addressed in the near future to take full advantage of all the research done in this field. The inconsistent or even conflicting results among some studies underscore the need for a unique metabolic health definition that is agreed upon by everyone in the research community. There must be consensus regarding not only the criteria and their cut-off values but also the number of risk factors that determine the MHO phenotype. Until then, the interpretation and comparison of the results from different study groups will remain difficult, if not impossible. Another challenge is to go beyond pilot molecular studies with small numbers of participants and develop national and international collaborative networks. Larger sample sizes should address the issues of heterogeneity among study participants, as well as difficulties in the recruitment of the most MHO individuals, who do not exhibit any of the risk factors despite their obesity. Another issue that needs to be considered is that only a few studies on metabolic health have applied the global analysis approach in the form of omics technologies, likely because of the high cost combined with the limited funds of pilot studies. Ideally, a large-scale study on universally defined metabolic health phenotypes should be carried out, implementing all omics technologies and therefore exploring metabolic function comprehensively at all possible levels: genomic, transcriptomic, epigenomic, proteomic, and metabolomic, as well as that of the gut microbiota. The markers identified with different omics methods can then be fitted into a multi-omics framework, revealing the interplay between molecules or pathways and the roles of different factors in mechanisms underlying metabolic health deterioration.

**REFERENCES**

1 **World Health Organization**. Obesity and overweight. 2020 April 1. [cited 17 December 2020]. In: World Health Organization [Internet]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

2 **Jarolimova J**, Tagoni J, Stern TA. Obesity: its epidemiology, comorbidities, and management. *Prim Care Companion CNS Disord* 2013; **15** [PMID: 24511434 DOI: 10.4088/PCC.12f01475]

3 **Sims EA**. Are there persons who are obese, but metabolically healthy? *Metabolism* 2001; **50**: 1499-1504 [PMID: 11735101 DOI: 10.1053/meta.2001.27213]

4 **Klöting N**, Fasshauer M, Dietrich A, Kovacs P, Schön MR, Kern M, Stumvoll M, Blüher M. Insulin-sensitive obesity. *Am J Physiol Endocrinol Metab* 2010; **299**: E506-E515 [PMID: 20570822 DOI: 10.1152/ajpendo.00586.2009]

5 **Blüher M**. Metabolically Healthy Obesity. *Endocr Rev* 2020; **41** [PMID: 32128581 DOI: 10.1210/endrev/bnaa004]

6 **Duque AP**, Rodrigues Junior LF, Mediano MFF, Tibiriça E, De Lorenzo A. Emerging concepts in metabolically healthy obesity. *Am J Cardiovasc Dis* 2020; **10**: 48-61 [PMID: 32685263]

7 **Brandão I**, Martins MJ, Monteiro R. Metabolically Healthy Obesity-Heterogeneity in Definitions and Unconventional Factors. *Metabolites* 2020; **10** [PMID: 32012784 DOI: 10.3390/metabo10020048]

8 **Böhm A**, Halama A, Meile T, Zdichavsky M, Lehmann R, Weigert C, Fritsche A, Stefan N, Königsrainer A, Häring HU, de Angelis MH, Adamski J, Staiger H. Metabolic signatures of cultured human adipocytes from metabolically healthy *vs* unhealthy obese individuals. *PLoS One* 2014; **9**: e93148 [PMID: 24695116 DOI: 10.1371/journal.pone.0093148]

9 **Naukkarinen J**, Heinonen S, Hakkarainen A, Lundbom J, Vuolteenaho K, Saarinen L, Hautaniemi S, Rodriguez A, Frühbeck G, Pajunen P, Hyötyläinen T, Orešič M, Moilanen E, Suomalainen A, Lundbom N, Kaprio J, Rissanen A, Pietiläinen KH. Characterising metabolically healthy obesity in weight-discordant monozygotic twins. *Diabetologia* 2014; **57**: 167-176 [PMID: 24100782 DOI: 10.1007/s00125-013-3066-y]

10 **Liu C**, Wang C, Guan S, Liu H, Wu X, Zhang Z, Gu X, Zhang Y, Zhao Y, Tse LA, Fang X. The Prevalence of Metabolically Healthy and Unhealthy Obesity according to Different Criteria. *Obes Facts* 2019; **12**: 78-90 [PMID: 30814477 DOI: 10.1159/000495852]

11 **Rey-López JP**, de Rezende LF, Pastor-Valero M, Tess BH. The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used. *Obes Rev* 2014; **15**: 781-790 [PMID: 25040597 DOI: 10.1111/obr.12198]

12 **Lin H**, Zhang L, Zheng R, Zheng Y. The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis: A PRISMA-compliant article. *Medicine (Baltimore)* 2017; **96**: e8838 [PMID: 29381992 DOI: 10.1097/MD.0000000000008838]

13 **van Vliet-Ostaptchouk JV**, Nuotio ML, Slagter SN, Doiron D, Fischer K, Foco L, Gaye A, Gögele M, Heier M, Hiekkalinna T, Joensuu A, Newby C, Pang C, Partinen E, Reischl E, Schwienbacher C, Tammesoo ML, Swertz MA, Burton P, Ferretti V, Fortier I, Giepmans L, Harris JR, Hillege HL, Holmen J, Jula A, Kootstra-Ros JE, Kvaløy K, Holmen TL, Männistö S, Metspalu A, Midthjell K, Murtagh MJ, Peters A, Pramstaller PP, Saaristo T, Salomaa V, Stolk RP, Uusitupa M, van der Harst P, van der Klauw MM, Waldenberger M, Perola M, Wolffenbuttel BH. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. *BMC Endocr Disord* 2014; **14**: 9 [PMID: 24484869 DOI: 10.1186/1472-6823-14-9]

14 **de Rooij BH**, van der Berg JD, van der Kallen CJ, Schram MT, Savelberg HH, Schaper NC, Dagnelie PC, Henry RM, Kroon AA, Stehouwer CD, Koster A. Physical Activity and Sedentary Behavior in Metabolically Healthy *vs* Unhealthy Obese and Non-Obese Individuals - The Maastricht Study. *PLoS One* 2016; **11**: e0154358 [PMID: 27138596 DOI: 10.1371/journal.pone.0154358]

15 **Santovito D**. Fat or fit: The big oxymoron of (metabolically) healthy obesity. *Atherosclerosis* 2017; **262**: 143-145 [PMID: 28499608 DOI: 10.1016/j.atherosclerosis.2017.04.020]

16 **Eckel N**, Meidtner K, Kalle-Uhlmann T, Stefan N, Schulze MB. Metabolically healthy obesity and cardiovascular events: A systematic review and meta-analysis. *Eur J Prev Cardiol* 2016; **23**: 956-966 [PMID: 26701871 DOI: 10.1177/2047487315623884]

17 **Bell JA**, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. *Obes Rev* 2014; **15**: 504-515 [PMID: 24661566 DOI: 10.1111/obr.12157]

18 **Opio J**, Croker E, Odongo GS, Attia J, Wynne K, McEvoy M. Metabolically healthy overweight/obesity are associated with increased risk of cardiovascular disease in adults, even in the absence of metabolic risk factors: A systematic review and meta-analysis of prospective cohort studies. *Obes Rev* 2020; **21**: e13127 [PMID: 32869512 DOI: 10.1111/obr.13127]

19 **Mongraw-Chaffin M**, Foster MC, Anderson CAM, Burke GL, Haq N, Kalyani RR, Ouyang P, Sibley CT, Tracy R, Woodward M, Vaidya D. Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk. *J Am Coll Cardiol* 2018; **71**: 1857-1865 [PMID: 29699611 DOI: 10.1016/j.jacc.2018.02.055]

20 **Goossens GH**. The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function. *Obes Facts* 2017; **10**: 207-215 [PMID: 28564650 DOI: 10.1159/000471488]

21 **Huang LO**, Loos RJF, Kilpeläinen TO. Evidence of genetic predisposition for metabolically healthy obesity and metabolically obese normal weight. *Physiol Genomics* 2018; **50**: 169-178 [PMID: 29341865 DOI: 10.1152/physiolgenomics.00044.2017]

22 **Iacomino G**, Siani A. Role of microRNAs in obesity and obesity-related diseases. *Genes Nutr* 2017; **12**: 23 [PMID: 28974990 DOI: 10.1186/s12263-017-0577-z]

23 **Pascale A**, Marchesi N, Marelli C, Coppola A, Luzi L, Govoni S, Giustina A, Gazzaruso C. Microbiota and metabolic diseases. *Endocrine* 2018; **61**: 357-371 [PMID: 29721802 DOI: 10.1007/s12020-018-1605-5]

24 **Dong SS**, Zhang YJ, Chen YX, Yao S, Hao RH, Rong Y, Niu HM, Chen JB, Guo Y, Yang TL. Comprehensive review and annotation of susceptibility SNPs associated with obesity-related traits. *Obes Rev* 2018; **19**: 917-930 [PMID: 29527783 DOI: 10.1111/obr.12677]

25 **Bomba L**, Walter K, Soranzo N. The impact of rare and low-frequency genetic variants in common disease. *Genome Biol* 2017; **18**: 77 [PMID: 28449691 DOI: 10.1186/s13059-017-1212-4]

26 **Schlauch KA**, Kulick D, Subramanian K, De Meirleir KL, Palotás A, Lombardi VC. Single-nucleotide polymorphisms in a cohort of significantly obese women without cardiometabolic diseases. *Int J Obes (Lond)* 2019; **43**: 253-262 [PMID: 30120429 DOI: 10.1038/s41366-018-0181-3]

27 **Gharooi Ahangar O**, Javanrouh N, Daneshpour MS, Barzin M, Valizadeh M, Azizi F, Hosseinpanah F. Genetic markers and continuity of healthy metabolic status: Tehran cardio-metabolic genetic study (TCGS). *Sci Rep* 2020; **10**: 13600 [PMID: 32788640 DOI: 10.1038/s41598-020-70627-5]

28 **Sedaghati-Khayat B**, Barzin M, Akbarzadeh M, Guity K, Fallah MS, Pourhassan H, Azizi F, Daneshpour MS. Lack of association between FTO gene variations and metabolic healthy obese (MHO) phenotype: Tehran Cardio-metabolic Genetic Study (TCGS). *Eat Weight Disord* 2020; **25**: 25-35 [PMID: 29525920 DOI: 10.1007/s40519-018-0493-2]

29 **Gao L**, Wang L, Yang H, Pan H, Gong F, Zhu H. *MC4R* Single Nucleotide Polymorphisms Were Associated with Metabolically Healthy and Unhealthy Obesity in Chinese Northern Han Populations. *Int J Endocrinol* 2019; **2019**: 4328909 [PMID: 31781208 DOI: 10.1155/2019/4328909]

30 **Jamka M**, Kaczmarek N, Mądry E, Krzyżanowska-Jankowska P, Bajerska J, Kręgielska-Narożna M, Bogdański P, Walkowiak J. Metabolic Health in Obese Subjects-Is There a Link to Lactoferrin and Lactoferrin Receptor-Related Gene Polymorphisms? *Nutrients* 2020; **12** [PMID: 32957486 DOI: 10.3390/nu12092843]

31 **Berezina A**, Belyaeva O, Berkovich O, Baranova E, Karonova T, Bazhenova E, Brovin D, Grineva E, Shlyakhto E. Prevalence, Risk Factors, and Genetic Traits in Metabolically Healthy and Unhealthy Obese Individuals. *Biomed Res Int* 2015; **2015**: 548734 [PMID: 26504811 DOI: 10.1155/2015/548734]

32 **Chang CS**, Lu YJ, Chang HH, Hsu SH, Kuo PH, Shieh CC, Yao WJ, Hsu MC, Young KC, Lin WY, Huang KC, Wu CH, Tsai YS. Role of adiponectin gene variants, adipokines and hydrometry-based percent body fat in metabolically healthy and abnormal obesity. *Obes Res Clin Pract* 2018; **12**: 49-61 [PMID: 27236826 DOI: 10.1016/j.orcp.2016.05.003]

33 **Casamassimi A**, Federico A, Rienzo M, Esposito S, Ciccodicola A. Transcriptome Profiling in Human Diseases: New Advances and Perspectives. *Int J Mol Sci* 2017; **18** [PMID: 28758927 DOI: 10.3390/ijms18081652]

34 **Gaye A**, Doumatey AP, Davis SK, Rotimi CN, Gibbons GH. Whole-genome transcriptomic insights into protective molecular mechanisms in metabolically healthy obese African Americans. *NPJ Genom Med* 2018; **3**: 4 [PMID: 29387454 DOI: 10.1038/s41525-018-0043-x]

35 **Paczkowska-Abdulsalam M**, Niemira M, Bielska A, Szałkowska A, Raczkowska BA, Junttila S, Gyenesei A, Adamska-Patruno E, Maliszewska K, Citko A, Szczerbiński Ł, Krętowski A. Evaluation of Transcriptomic Regulations behind Metabolic Syndrome in Obese and Lean Subjects. *Int J Mol Sci* 2020; **21** [PMID: 32093387 DOI: 10.3390/ijms21041455]

36 **de Luis DA**, Almansa R, Aller R, Izaola O, Romero E. Gene expression analysis identify a metabolic and cell function alterations as a hallmark of obesity without metabolic syndrome in peripheral blood, a pilot study. *Clin Nutr* 2018; **37**: 1348-1353 [PMID: 28633944 DOI: 10.1016/j.clnu.2017.06.006]

37 **Das SK**, Ma L, Sharma NK. Adipose tissue gene expression and metabolic health of obese adults. *Int J Obes (Lond)* 2015; **39**: 869-873 [PMID: 25520251 DOI: 10.1038/ijo.2014.210]

38 **Bhansali S**, Bhansali A, Dhawan V. Favourable metabolic profile sustains mitophagy and prevents metabolic abnormalities in metabolically healthy obese individuals. *Diabetol Metab Syndr* 2017; **9**: 99 [PMID: 29255491 DOI: 10.1186/s13098-017-0298-x]

39 **Bañuls C**, Rovira-Llopis S, Lopez-Domenech S, Diaz-Morales N, Blas-Garcia A, Veses S, Morillas C, Victor VM, Rocha M, Hernandez-Mijares A. Oxidative and endoplasmic reticulum stress is impaired in leukocytes from metabolically unhealthy *vs* healthy obese individuals. *Int J Obes (Lond)* 2017; **41**: 1556-1563 [PMID: 28630460 DOI: 10.1038/ijo.2017.147]

40 **Amiri P**, Baradaran B, Saghafi-Asl M, Naghizadeh M, Shanehbandi D, Karamzad N, Vahed SZ. Association of proinflammatory genes expression with serum interleukin 1β and free fatty acids in metabolically healthy and unhealthy abdominally obese individuals: a case-control study. *BMC Immunol* 2019; **20**: 23 [PMID: 31272370 DOI: 10.1186/s12865-019-0303-2]

41 **Naghizadeh M**, Baradaran B, Saghafi-Asl M, Amiri P, Shanehbandi D, Karamzad N, Mohamed-Khosroshahi L. Toll-like receptor signaling and serum levels of interferon β and lipopolysaccharide binding protein are related to abdominal obesity: a case-control study between metabolically healthy and metabolically unhealthy obese individuals. *Nutr Res* 2018; **55**: 11-20 [PMID: 29914624 DOI: 10.1016/j.nutres.2018.03.014]

42 **Telle-Hansen VH**, Halvorsen B, Dalen KT, Narverud I, Wesseltoft-Rao N, Granlund L, Ulven SM, Holven KB. Altered expression of genes involved in lipid metabolism in obese subjects with unfavourable phenotype. *Genes Nutr* 2013; **8**: 425-434 [PMID: 23296345 DOI: 10.1007/s12263-012-0329-z]

43 **Gómez-Ambrosi J**, Catalán V, Rodríguez A, Andrada P, Ramírez B, Ibáñez P, Vila N, Romero S, Margall MA, Gil MJ, Moncada R, Valentí V, Silva C, Salvador J, Frühbeck G. Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy. *Diabetes Care* 2014; **37**: 2813-2821 [PMID: 25011950 DOI: 10.2337/dc14-0937]

44 **Matsuyama H**, Suzuki HI. Systems and Synthetic microRNA Biology: From Biogenesis to Disease Pathogenesis. *Int J Mol Sci* 2019; **21** [PMID: 31878193 DOI: 10.3390/ijms21010132]

45 **Liu W**, Wang X. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. *Genome Biol* 2019; **20**: 18 [PMID: 30670076 DOI: 10.1186/s13059-019-1629-z]

46 **Vienberg S**, Geiger J, Madsen S, Dalgaard LT. MicroRNAs in metabolism. *Acta Physiol (Oxf)* 2017; **219**: 346-361 [PMID: 27009502 DOI: 10.1111/apha.12681]

47 **Yang P**, Dong X, Zhang Y. MicroRNA profiles in plasma samples from young metabolically healthy obese patients and miRNA-21 are associated with diastolic dysfunction *via* TGF-β1/Smad pathway. *J Clin Lab Anal* 2020; **34**: e23246 [PMID: 32108968 DOI: 10.1002/jcla.23246]

48 **Doumatey AP**, He WJ, Gaye A, Lei L, Zhou J, Gibbons GH, Adeyemo A, Rotimi CN. Circulating MiR-374a-5p is a potential modulator of the inflammatory process in obesity. *Sci Rep* 2018; **8**: 7680 [PMID: 29769661 DOI: 10.1038/s41598-018-26065-5]

49 **Yue HQ**, Zhou YH, Guo Y, Tang CY, Wang F, Zhou HD. Serum miR-503 is a Candidate Biomarker for Differentiating Metabolic Healthy Obesity from Metabolic Unhealthy Obesity. *Diabetes Metab Syndr Obes* 2020; **13**: 2667-2676 [PMID: 32821139 DOI: 10.2147/DMSO.S262888]

50 **Dahlman I**, Belarbi Y, Laurencikiene J, Pettersson AM, Arner P, Kulyté A. Comprehensive functional screening of miRNAs involved in fat cell insulin sensitivity among women. *Am J Physiol Endocrinol Metab* 2017; **312**: E482-E494 [PMID: 28270439 DOI: 10.1152/ajpendo.00251.2016]

51 **Jones A**, Danielson KM, Benton MC, Ziegler O, Shah R, Stubbs RS, Das S, Macartney-Coxson D. miRNA Signatures of Insulin Resistance in Obesity. *Obesity (Silver Spring)* 2017; **25**: 1734-1744 [PMID: 28834285 DOI: 10.1002/oby.21950]

52 **Conerly M**, Grady WM. Insights into the role of DNA methylation in disease through the use of mouse models. *Dis Model Mech* 2010; **3**: 290-297 [PMID: 20427558 DOI: 10.1242/dmm.004812]

53 **Jin Z**, Liu Y. DNA methylation in human diseases. *Genes Dis* 2018; **5**: 1-8 [PMID: 30258928 DOI: 10.1016/j.gendis.2018.01.002]

54 **Turcot V**, Tchernof A, Deshaies Y, Pérusse L, Bélisle A, Marceau S, Biron S, Lescelleur O, Biertho L, Vohl MC. LINE-1 methylation in visceral adipose tissue of severely obese individuals is associated with metabolic syndrome status and related phenotypes. *Clin Epigenetics* 2012; **4**: 10 [PMID: 22748066 DOI: 10.1186/1868-7083-4-10]

55 **Turcot V**, Tchernof A, Deshaies Y, Pérusse L, Bélisle A, Marceau P, Hould FS, Lebel S, Vohl MC. Comparison of the dipeptidyl peptidase-4 gene methylation levels between severely obese subjects with and without the metabolic syndrome. *Diabetol Metab Syndr* 2013; **5**: 4 [PMID: 23379505 DOI: 10.1186/1758-5996-5-4]

56 **Guénard F**, Tchernof A, Deshaies Y, Pérusse L, Biron S, Lescelleur O, Biertho L, Marceau S, Vohl MC. Differential methylation in visceral adipose tissue of obese men discordant for metabolic disturbances. *Physiol Genomics* 2014; **46**: 216-222 [PMID: 24495915 DOI: 10.1152/physiolgenomics.00160.2013]

57 **Aslam B**, Basit M, Nisar MA, Khurshid M, Rasool MH. Proteomics: Technologies and Their Applications. *J Chromatogr Sci* 2017; **55**: 182-196 [PMID: 28087761 DOI: 10.1093/chromsci/bmw167]

58 **Doumatey AP**, Zhou J, Zhou M, Prieto D, Rotimi CN, Adeyemo A. Proinflammatory and lipid biomarkers mediate metabolically healthy obesity: A proteomics study. *Obesity (Silver Spring)* 2016; **24**: 1257-1265 [PMID: 27106679 DOI: 10.1002/oby.21482]

59 **Benabdelkamel H**, Masood A, Okla M, Al-Naami MY, Alfadda AA. A Proteomics-Based Approach Reveals Differential Regulation of Urine Proteins between Metabolically Healthy and Unhealthy Obese Patients. *Int J Mol Sci* 2019; **20** [PMID: 31623319 DOI: 10.3390/ijms20194905]

60 **Alfadda AA**, Masood A, Al-Naami MY, Chaurand P, Benabdelkamel H. A Proteomics Based Approach Reveals Differential Regulation of Visceral Adipose Tissue Proteins between Metabolically Healthy and Unhealthy Obese Patients. *Mol Cells* 2017; **40**: 685-695 [PMID: 28927258 DOI: 10.14348/molcells.2017.0073]

61 **Doulamis IP**, Konstantopoulos P, Tzani A, Antoranz A, Minia A, Daskalopoulou A, Charalampopoulos A, Alexopoulos L, Perrea DN, Menenakos E. Visceral white adipose tissue and serum proteomic alternations in metabolically healthy obese patients undergoing bariatric surgery. *Cytokine* 2019; **115**: 76-83 [PMID: 30472106 DOI: 10.1016/j.cyto.2018.11.017]

62 **Liu X**, Locasale JW. Metabolomics: A Primer. *Trends Biochem Sci* 2017; **42**: 274-284 [PMID: 28196646 DOI: 10.1016/j.tibs.2017.01.004]

63 **Clish CB**. Metabolomics: an emerging but powerful tool for precision medicine. *Cold Spring Harb Mol Case Stud* 2015; **1**: a000588 [PMID: 27148576 DOI: 10.1101/mcs.a000588]

64 **Wiklund PK**, Pekkala S, Autio R, Munukka E, Xu L, Saltevo J, Cheng S, Kujala UM, Alen M, Cheng S. Serum metabolic profiles in overweight and obese women with and without metabolic syndrome. *Diabetol Metab Syndr* 2014; **6**: 40 [PMID: 24650495 DOI: 10.1186/1758-5996-6-40]

65 **Chashmniam S**, Hashemi Madani N, Nobakht Mothlagh Ghoochani BF, Safari-Alighiarloo N, Khamseh ME. The metabolome profiling of obese and non-obese individuals: Metabolically healthy obese and unhealthy non-obese paradox. *Iran J Basic Med Sci* 2020; **23**: 186-194 [PMID: 32405361 DOI: 10.22038/IJBMS.2019.37885.9004]

66 **Badoud F**, Lam KP, DiBattista A, Perreault M, Zulyniak MA, Cattrysse B, Stephenson S, Britz-McKibbin P, Mutch DM. Serum and adipose tissue amino acid homeostasis in the metabolically healthy obese. *J Proteome Res* 2014; **13**: 3455-3466 [PMID: 24933025 DOI: 10.1021/pr500416v]

67 **Chen HH**, Tseng YJ, Wang SY, Tsai YS, Chang CS, Kuo TC, Yao WJ, Shieh CC, Wu CH, Kuo PH. The metabolome profiling and pathway analysis in metabolic healthy and abnormal obesity. *Int J Obes (Lond)* 2015; **39**: 1241-1248 [PMID: 25907313 DOI: 10.1038/ijo.2015.65]

68 **Zhong F**, Xu M, Bruno RS, Ballard KD, Zhu J. Targeted High Performance Liquid Chromatography Tandem Mass Spectrometry-based Metabolomics differentiates metabolic syndrome from obesity. *Exp Biol Med (Maywood)* 2017; **242**: 773-780 [PMID: 28299975 DOI: 10.1177/1535370217694098]

69 **Bagheri M**, Farzadfar F, Qi L, Yekaninejad MS, Chamari M, Zeleznik OA, Kalantar Z, Ebrahimi Z, Sheidaie A, Koletzko B, Uhl O, Djazayery A. Obesity-Related Metabolomic Profiles and Discrimination of Metabolically Unhealthy Obesity. *J Proteome Res* 2018; **17**: 1452-1462 [PMID: 29493238 DOI: 10.1021/acs.jproteome.7b00802]

70 **Gao X**, Zhang W, Wang Y, Pedram P, Cahill F, Zhai G, Randell E, Gulliver W, Sun G. Serum metabolic biomarkers distinguish metabolically healthy peripherally obese from unhealthy centrally obese individuals. *Nutr Metab (Lond)* 2016; **13**: 33 [PMID: 27175209 DOI: 10.1186/s12986-016-0095-9]

71 **Candi E**, Tesauro M, Cardillo C, Lena AM, Schinzari F, Rodia G, Sica G, Gentileschi P, Rovella V, Annicchiarico-Petruzzelli M, Di Daniele N, Melino G. Metabolic profiling of visceral adipose tissue from obese subjects with or without metabolic syndrome. *Biochem J* 2018; **475**: 1019-1035 [PMID: 29437994 DOI: 10.1042/BCJ20170604]

72 **Galavotti S**, Gescher AJ, Rufini A. Metabolites in visceral fat: useful signals of metabolic syndrome? *Biochem J* 2018; **475**: 1789-1791 [DOI: 10.1042/BCJ20180088]

73 **Thursby E**, Juge N. Introduction to the human gut microbiota. *Biochem J* 2017; **474**: 1823-1836 [PMID: 28512250 DOI: 10.1042/BCJ20160510]

74 **Durack J**, Lynch SV. The gut microbiome: Relationships with disease and opportunities for therapy. *J Exp Med* 2019; **216**: 20-40 [PMID: 30322864 DOI: 10.1084/jem.20180448]

75 **Mizrahi-Man O**, Davenport ER, Gilad Y. Taxonomic classification of bacterial 16S rRNA genes using short sequencing reads: evaluation of effective study designs. *PLoS One* 2013; **8**: e53608 [PMID: 23308262 DOI: 10.1371/journal.pone.0053608]

76 **Kim MH**, Yun KE, Kim J, Park E, Chang Y, Ryu S, Kim HL, Kim HN. Gut microbiota and metabolic health among overweight and obese individuals. *Sci Rep* 2020; **10**: 19417 [PMID: 33173145 DOI: 10.1038/s41598-020-76474-8]

77 **Chávez-Carbajal A**, Nirmalkar K, Pérez-Lizaur A, Hernández-Quiroz F, Ramírez-Del-Alto S, García-Mena J, Hernández-Guerrero C. Gut Microbiota and Predicted Metabolic Pathways in a Sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome. *Int J Mol Sci* 2019; **20** [PMID: 30669548 DOI: 10.3390/ijms20020438]

78 **Zhong X**, Harrington JM, Millar SR, Perry IJ, O'Toole PW, Phillips CM. Gut Microbiota Associations with Metabolic Health and Obesity Status in Older Adults. *Nutrients* 2020; **12** [PMID: 32784721 DOI: 10.3390/nu12082364]

79 **Kashtanova DA**, Tkacheva ON, Doudinskaya EN, Strazhesko ID, Kotovskaya YV, Popenko AS, Tyakht AV, Alexeev DG. Gut Microbiota in Patients with Different Metabolic Statuses: Moscow Study. *Microorganisms* 2018; **6** [PMID: 30257444 DOI: 10.3390/microorganisms6040098]

**Footnotes**

**Conflict-of-interest statement:** Authors have nothing to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 12, 2021

**First decision:** February 12, 2021

**Article in press:**

**Specialty type:** Endocrinology and metabolism

**Country/Territory of origin:** Poland

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Zhu Y **S-Editor:** Gao CC **L-Editor: P-Editor:**

**Figure Legends**



**Figure 1 Differences in characteristics between metabolically healthy obese and metabolically unhealthy obese individuals.** MHO: Metabolically healthy obese; MUO: Metabolically unhealthy obese.



**Figure 2 Different molecular levels targeted by a multi-omics approach.**

**Table 1 Single nucleotide polymorphisms associated with metabolically healthy obese phenotype**

|  |  |  |
| --- | --- | --- |
| **Nearest gene** | **SNPs** | **Ref.** |
| *ADIPOQ* | rs2241766 | Berezina *et al*[31] and Chang *et al*[32] |
| *MC4R* | rs2331841 | Gao *et al*[29] |
| *LTF* | rs2239692 | Jamka *et al*[30] |
| *FTO* | rs1121980 | Gharooi Ahangar *et al*[27] |
| *TCF7L2* | rs7903146 | Gharooi Ahangar *et al*[27] |
| *SLC39A8* | rs13107325 | Gharooi Ahangar *et al*[27] |
| *RTP4* | rs9028, rs9843429 | Schlauch *et al*[26] |
| *CDH18* | rs1022207, rs2967027 | Schlauch *et al*[26] |
| *FST/LOC257396* | rs37785, rs10461563 | Schlauch *et al*[26] |
| *FSTL4/WSPAR* | rs7719102, rs4246020 | Schlauch *et al*[26] |
| *LOC107986637* | rs11753543, rs9384860 | Schlauch *et al*[26] |
| *TRPS1* | rs2245221, rs2737214, rs2737215 | Schlauch *et al*[26] |
| *DLG2* | rs7131460, rs12275254 | Schlauch *et al*[26] |
| *TOX2* | rs766622, rs6065690, rs6093921 | Schlauch *et al*[26] |
| *FAM19A2/SLC16A7* | rs4143650, rs6581305 | Schlauch *et al*[26] |
| *LOC101927367/LOC105371833* | rs11079177, rs12601773 | Schlauch *et al*[26] |
| *LOC105371989* | rs206549, rs206547 | Schlauch *et al*[26] |
| *LOC107986666* | rs9295227, rs9458896, rs6928576, rs6902153, rs10945918, rs7748991, rs9356148 | Schlauch *et al*[26] |

SNPs: Single nucleotide polymorphisms.

**Table 2 Studies investigating genome-wide gene expression levels in metabolically healthy obese individuals**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Biological material** | **Method** | **Study design** | **Sample size** | **Metabolic health definition** | **Main findings** | **Ref.** |
| Whole blood | RNA-seq | MHO *vs* MUO | 8/21 | All conditions must be met: BP ≤ 130/85 mmHg, no medication; FPG ≤ 100 mg/dL, no medication; HOMA-IR ≤ 5.1; TG/HDL ≤ 1.65 for males, TG/HDL ≤ 1.32 for females; hsCRP ≤ 0.3 mg/dL | Enrichment in pathways: EIF2 signaling, eIF4 and p70S6K signaling, mTOR signaling. Enrichment in GO terms related to mRNA translation processes. Ribosomal protein genes among top differentially genes | Gaye *et al*[34] |
| Whole blood | RNA-seq | MHO *vs* MUO | 8/8 | No MetS, according to harmonized MetS definition | Enrichment in pathways: granulocyte/agranulocyte adhesion and diapedesis, coagulation system, intrinsic prothrombin activation pathway, atherosclerosis signaling, integrin signaling, binding and aggregation of blood cells | Paczkowska-Abdulsalam *et al*[35] |
| Whole blood | RNA-seq | MHO *vs* MHNW | 8/8 | No MetS, according to harmonized MetS definition | Enrichment in pathways: EIF2 signaling, eIF4 and p70S6K signaling, mTOR signaling, oxidative phosphorylation, mitochondrial dysfunction, vascular/arterial disease | Paczkowska-Abdulsalam *et al*[35] |
| PBMCs | Microarray | MHO *vs* MHNW | 17/15 | No MetS, according to NCEP ATP III MetS definition | Enrichment in pathways: carbohydrate metabolism, lipid metabolism, protein synthesis, amino acid metabolism, cell morphology, death and survival, cell-to-cell signaling and interaction, cellular development, movement, growth and proliferation | de Luis *et al*[36] |
| aSAT | Microarray | MHO *vs* MUO | 16/14 | MHO group identified through unsupervised hierarchical clustering of 1595 obesity-associated transcripts | Enrichment in pathways: complement system, TREM1 signaling, IL-8 signaling, actin cytoskeleton signaling, vascular disease, occlusion of artery | Das *et al*[37] |

aSAT: Abdominal subcutaneous adipose tissue; PBMCs: Peripheral blood mononuclear cells; NCEP ATPIII: National Cholesterol Education Program Adult Treatment Panel III; BP: Blood pressure; FPG: Fasting plasma glucose; HOMA-IR: Homeostatic model assessment for insulin resistance; TG: Triglycerides; HDL: High-density lipoprotein; CRP: C-reactive protein; MHO: Metabolically healthy obese; IL: Interleukin.

**Table 3 Different expression of micro-RNAs identified in metabolically healthy obese individuals**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **miRNA** | **Upregulation/ Downregulation** | **Sample size (MHO/MHNW)** | **Biological material** | **Ref.** |
| **MHO *vs* MHNW** | | | | |
| hsa-miR-5001 | **↓** | 6/6 | Plasma | Yang *et al*[47] |
| hsa-miR-4541 | **↓** |
| hsa-miR-142 | **↓** |
| hsa-miR-320a1 | **↓** |
| hsa-miR-107 | **↓** |
| hsa-miR-34a | **↑** |
| hsa-miR-211 | **↑** |
| hsa-miR-99b | **↑** |
| hsa-miR-148a1 | **↑** |
| hsa-miR-1261 | **↑** |
| **MHO *vs* MUO** | | | | |
| hsa-miR-223-3p | **↓** | 10/10 | Serum | Doumatey *et al*[48] |
| hsa-miR-374a-5p1 | **↑** |
| hsa-miR-10b-5p | **↑** |
| hsa-miR-26b-5p | **↑** |
| hsa-let-7d-3p | **↑** |
| hsa-miR-29a-3p | **↑** |
| hsa-miR-342-3p | **↑** |
| hsa-miR-16-2-3p | **↑** |
| hsa-miR-503 | **↑** | 34/21 | Serum | Yue *et al*[49] |

1Validated with real-time reverse transcription polymerase chain reaction in an independent cohort. miRNA: Micro-RNAs; MHO: Metabolically healthy obese; MHNW: Metabolically healthy normal weight; MUO: Metabolically unhealthy obese.

**Table 4 Proteins with altered expression in metabolically healthy obese compared to metabolically unhealthy obese individuals**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Biological material** | **Over-expressed** | **Under-expressed** | **Top enriched pathways** | **Ref.** |
| Serum | APOB, AHSG, SERPINC1, APOA4, SERPING1, RBP4, ITIH2, GSN, HRG, ITIH1, GC, C7 | HBA1, HPR, HBB, CFB, ITIH4, CRP, PON1, C4A | LXR/RXR activation, FXR/RXR activation, acute phase response signaling, complement system, atherosclerosis signaling, IL-12 signaling and production in macrophages, production of nitric oxide and reactive oxygen species in macrophages, clathrin-mediated endocytosis signaling, extrinsic prothrombin activation pathway, intrinsic prothrombin activation pathway, coagulation system | Doumatey *et al*[58] |
| Urine | RASN, IGHG2, K1C10, VTDB | ACOT2, ARL15, APC4, APC7, APOA1, DYH3, FIBA, C1GLT, HIX, ITIH4, KNG1, P3H2, AMBP, COO33, RET4, TRFE, ZFP2, ZN568, ZN655 | LXR/RXR activation, FXR/RXR activation, acute phase response signaling, clathrin-mediated endocytosis signaling, atherosclerosis signaling, IL-12 signaling and production in macrophages, coagulation system, intrinsic prothrombin activation pathway, production of nitric oxide and reactive oxygen species in macrophages, systemic lupus erythematosus signaling | Benabdelkamel *et al*[59] |
| VAT | ANXA5, ACTG, ACTB, LEG1, GPDA, APOA1, CO6A1, SBP1, CATA, TO20L, BRE1A, RNA58, SOX21 | POTEE, SPTN4, GDIR1, TTHY, HSP1, PPIA, UPAR, PAI1, BLVRB, ERI2, YQ019 | death receptor signaling, coagulation system, acute phase response signaling, RhoGDI signaling, NRF2-mediated oxidative stress response | Alfadda *et al*[60] |

IL: Interleukin; VAT: Visceral adipose tissue; LXR: Liver X receptor; RXR: Retinoid X receptor, FXR: Farnesoid X receptor; NRF2: Nuclear factor erythroid 2-related factor 2; RhoGDI: Rho GDP-dissociation inhibitor.

**Table 5 Differentially regulated pathways between metabolically healthy obese and metabolically unhealthy obese groups identified by metabolomics studies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study** | **Chen *et al*[67], 2015** | **Zhong *et al*[68], 2017** | **Candi *et al*[71], 2018** | **Chashmniam *et al*[65], 2020** |
| Biological material | Plasma | Plasma | VAT | Serum |
| Method | LC-MS, GC-MS | LC-MS/MS | LC-MS/MS | NMR |
| MHO definition | No MetS, according to NCEP ATP III MetS definition | No MetS, according to harmonized MetS definition | No MetS, according to NCEP ATP III MetS definition | No MetS, according to NCEP ATP III MetS definition |
| MHO (*n*) | 34 | 43 | 18 | 21 |
| MUO (*n*) | 34 | 26 | 18 | 21 |
| Affected pathways | Fatty acid biosynthesis; Phenylalanine metabolism; Propanoate metabolism; Valine, leucine and isoleucine degradation; Pyrimidine metabolism; Citrate cycle (TCA cycle); Galactose metabolism; Glyoxylate and dicarboxylate; and Tryptophan metabolism | Purine metabolism (*i.e.*, urate); Valine, leucine and isoleucine degradation; Aminoacyl-tRNA biosynthesis; Tryptophan metabolism; Cysteine and methionine metabolism; Lysine degradation; Pyrimidine metabolism; Arginine and proline metabolism; Glycine, serine and threonine metabolism; Taurine and hypotaurine metabolism; Alanine, aspartate and glutamate metabolism; Pantothenate and CoA biosynthesis | Ceramide metabolism; Phosphatidylserine; Fatty acid, dicarboxylate; Glutathione metabolism; Lysoplasmalogen; Lysolipid; Aminosugar metabolism; Gamma-glutamyl amino acid; Pyrimidine metabolism, uracyl containing; Plasmalogen; Glycerolipid metabolism; Sphingolipid metabolism; Phopsholipid metabolism; Fructose, mannose, and galactose metabolism | Urea cycle; Ammonia recycling; Aspartate metabolism; Glycine and serine metabolism; Glucose-alanine cycle; and Arginine and proline metabolism |

LC: Liquid chromatography; GC: Gas chromatography; MS: Mass spectrometry; NCEP ATP III: National Cholesterol Education Program Adult Treatment Panel III; TCA: Citric acid cycle; MetS: Metabolic syndrome; NMR: Nuclear magnetic resonance; MHO: Metabolically healthy obese; MUO: Metabolically unhealthy obese.